Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer.

Yao W, Rose JL, Wang W, Seth S, Jiang H, Taguchi A, Liu J, Yan L, Kapoor A, Hou P, Chen Z, Wang Q, Nezi L, Xu Z, Yao J, Hu B, Pettazzoni PF, Ho IL, Feng N, Ramamoorthy V, Jiang S, Deng P, Ma GJ, Den P, Tan Z, Zhang SX, Wang H, Wang YA, Deem AK, Fleming JB, Carugo A, Heffernan TP, Maitra A, Viale A, Ying H, Hanash S, DePinho RA, Draetta GF.

Nature. 2019 Apr;568(7752):410-414. doi: 10.1038/s41586-019-1062-1. Epub 2019 Mar 27.

PMID:
30918400
2.

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L.

Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5.

PMID:
30835824
3.

p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.

Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G.

Cancer Cell. 2019 Feb 11;35(2):204-220.e9. doi: 10.1016/j.ccell.2019.01.006.

PMID:
30753823
4.

Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors.

Seth S, Li CY, Ho IL, Corti D, Loponte S, Sapio L, Del Poggetto E, Yen EY, Robinson FS, Peoples M, Karpinets T, Deem AK, Kumar T, Song X, Jiang S, Kang Y, Fleming J, Kim M, Zhang J, Maitra A, Heffernan TP, Giuliani V, Genovese G, Futreal A, Draetta GF, Carugo A, Viale A.

Cell Rep. 2019 Feb 5;26(6):1518-1532.e9. doi: 10.1016/j.celrep.2019.01.048.

5.

Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation.

Sun Y, Bandi M, Lofton T, Smith M, Bristow CA, Carugo A, Rogers N, Leonard P, Chang Q, Mullinax R, Han J, Shi X, Seth S, Meyers BA, Miller M, Miao L, Ma X, Feng N, Giuliani V, Geck Do M, Czako B, Palmer WS, Mseeh F, Asara JM, Jiang Y, Morlacchi P, Zhao S, Peoples M, Tieu TN, Warmoes MO, Lorenzi PL, Muller FL, DePinho RA, Draetta GF, Toniatti C, Jones P, Heffernan TP, Marszalek JR.

Cell Rep. 2019 Jan 8;26(2):469-482.e5. doi: 10.1016/j.celrep.2018.12.043.

6.

An inhibitor of oxidative phosphorylation exploits cancer vulnerability.

Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver N, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR.

Nat Med. 2018 Jul;24(7):1036-1046. doi: 10.1038/s41591-018-0052-4. Epub 2018 Jun 11.

PMID:
29892070
7.

Collapsing the Tumor Ecosystem: Preventing Adaptive Response to Treatment by Inhibiting Transcription.

Carugo A, Draetta GF.

Cancer Discov. 2018 Jan;8(1):17-19. doi: 10.1158/2159-8290.CD-17-1245.

8.

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.

Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, Chintala S, Orillion A, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF, Seshadri M, Hancock B, Radovich M, Kota J, Buck M, Keilhack H, McCarthy BP, Persohn SA, Territo PR, Zang Y, Irudayaraj J, Tao WA, Hollenhorst P, Pili R.

Cancer Res. 2017 Dec 1;77(23):6651-6666. doi: 10.1158/0008-5472.CAN-17-0899. Epub 2017 Oct 4.

9.

How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Workman P, Draetta GF, Schellens JHM, Bernards R.

Cell. 2017 Feb 9;168(4):579-583. doi: 10.1016/j.cell.2017.01.034.

10.

Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.

Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L.

Nature. 2017 Feb 16;542(7641):362-366. doi: 10.1038/nature21064. Epub 2017 Feb 8.

PMID:
28178232
11.

Metabolic Features of Cancer Treatment Resistance.

Viale A, Draetta GF.

Recent Results Cancer Res. 2016;207:135-56. doi: 10.1007/978-3-319-42118-6_6. Review.

PMID:
27557537
12.

In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.

Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF, Akdemir KC, Bristow CA, Robinson FS, Tepper J, Sanchez N, Gupta S, Estecio MR, Giuliani V, Dellino GI, Riva L, Yao W, Di Francesco ME, Green T, D'Alesio C, Corti D, Kang Y, Jones P, Wang H, Fleming JB, Maitra A, Pelicci PG, Chin L, DePinho RA, Lanfrancone L, Heffernan TP, Draetta GF.

Cell Rep. 2016 Jun 28;16(1):133-147. doi: 10.1016/j.celrep.2016.05.063. Epub 2016 Jun 16.

13.

In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype.

Bossi D, Cicalese A, Dellino GI, Luzi L, Riva L, D'Alesio C, Diaferia GR, Carugo A, Cavallaro E, Piccioni R, Barberis M, Mazzarol G, Testori A, Punzi S, Pallavicini I, Tosti G, Giacó L, Melloni G, Heffernan TP, Natoli G, Draetta GF, Minucci S, Pelicci P, Lanfrancone L.

Cancer Discov. 2016 Jun;6(6):650-63. doi: 10.1158/2159-8290.CD-15-1200. Epub 2016 May 13.

14.

Genetics and biology of pancreatic ductal adenocarcinoma.

Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA.

Genes Dev. 2016 Feb 15;30(4):355-85. doi: 10.1101/gad.275776.115. Review.

15.

Post-translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair.

Gutschner T, Haemmerle M, Genovese G, Draetta GF, Chin L.

Cell Rep. 2016 Feb 16;14(6):1555-1566. doi: 10.1016/j.celrep.2016.01.019. Epub 2016 Feb 4.

16.

Sugar? No Thank You, Just a Deep Breath of Oxygen for Cancer Stem Cells.

Viale A, Draetta GF.

Cell Metab. 2015 Oct 6;22(4):543-5. doi: 10.1016/j.cmet.2015.09.020.

17.

Tumors and mitochondrial respiration: a neglected connection.

Viale A, Corti D, Draetta GF.

Cancer Res. 2015 Sep 15;75(18):3685-6. Review.

18.

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.

Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi L, Marchesini M, Kapoor A, Yao W, Francesco ME, Petrocchi A, Deem AK, Scott K, Colla S, Mills GB, Fleming JB, Heffernan TP, Jones P, Toniatti C, DePinho RA, Draetta GF.

Cancer Res. 2015 Mar 15;75(6):1091-101. doi: 10.1158/0008-5472.CAN-14-1854. Epub 2015 Mar 3.

19.

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.

Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, Kapoor A, Yao W, Brunetto E, Kang Y, Yuan M, Asara JM, Wang YA, Heffernan TP, Kimmelman AC, Wang H, Fleming JB, Cantley LC, DePinho RA, Draetta GF.

Nature. 2014 Oct 30;514(7524):628-32. doi: 10.1038/nature13611. Epub 2014 Aug 10.

20.

Investigative pathology: leading the post-genomic revolution.

Berman DM, Bosenberg MW, Orwant RL, Thurberg BL, Draetta GF, Fletcher CD, Loda M.

Lab Invest. 2012 Jan;92(1):4-8. doi: 10.1038/labinvest.2011.147. Epub 2011 Oct 10. Review.

21.

Cancer drug discovery faces the FACT.

Draetta GF, Depinho RA.

Sci Transl Med. 2011 Aug 10;3(95):95ps34. doi: 10.1126/scitranslmed.3002822.

PMID:
21832237
22.

Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.

Efferson CL, Winkelmann CT, Ware C, Sullivan T, Giampaoli S, Tammam J, Patel S, Mesiti G, Reilly JF, Gibson RE, Buser C, Yeatman T, Coppola D, Winter C, Clark EA, Draetta GF, Strack PR, Majumder PK.

Cancer Res. 2010 Mar 15;70(6):2476-84. doi: 10.1158/0008-5472.CAN-09-3114. Epub 2010 Mar 2.

23.

Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.

Rao SS, O'Neil J, Liberator CD, Hardwick JS, Dai X, Zhang T, Tyminski E, Yuan J, Kohl NE, Richon VM, Van der Ploeg LH, Carroll PM, Draetta GF, Look AT, Strack PR, Winter CG.

Cancer Res. 2009 Apr 1;69(7):3060-8. doi: 10.1158/0008-5472.CAN-08-4295. Epub 2009 Mar 24.

24.

Role for histone deacetylase 1 in human tumor cell proliferation.

Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, Chiocca S.

Mol Cell Biol. 2007 Jul;27(13):4784-95. Epub 2007 Apr 30.

25.

SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins.

Busino L, Bassermann F, Maiolica A, Lee C, Nolan PM, Godinho SI, Draetta GF, Pagano M.

Science. 2007 May 11;316(5826):900-4. Epub 2007 Apr 26.

26.

Frequent alterations in the expression of serine/threonine kinases in human cancers.

Capra M, Nuciforo PG, Confalonieri S, Quarto M, Bianchi M, Nebuloni M, Boldorini R, Pallotti F, Viale G, Gishizky ML, Draetta GF, Di Fiore PP.

Cancer Res. 2006 Aug 15;66(16):8147-54.

27.

Ebp1 is a dsRNA-binding protein associated with ribosomes that modulates eIF2alpha phosphorylation.

Squatrito M, Mancino M, Sala L, Draetta GF.

Biochem Biophys Res Commun. 2006 Jun 9;344(3):859-68. Epub 2006 Apr 19.

PMID:
16631606
29.

Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner.

Ray D, Terao Y, Nimbalkar D, Chu LH, Donzelli M, Tsutsui T, Zou X, Ghosh AK, Varga J, Draetta GF, Kiyokawa H.

Mol Cell Biol. 2005 Apr;25(8):3338-47.

30.

A mechanism for inhibiting the SUMO pathway.

Boggio R, Colombo R, Hay RT, Draetta GF, Chiocca S.

Mol Cell. 2004 Nov 19;16(4):549-61.

31.

EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes.

Squatrito M, Mancino M, Donzelli M, Areces LB, Draetta GF.

Oncogene. 2004 May 27;23(25):4454-65.

PMID:
15064750
32.

Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis.

Busino L, Chiesa M, Draetta GF, Donzelli M.

Oncogene. 2004 Mar 15;23(11):2050-6. Review.

PMID:
15021892
33.

Hierarchical order of phosphorylation events commits Cdc25A to betaTrCP-dependent degradation.

Donzelli M, Busino L, Chiesa M, Ganoth D, Hershko A, Draetta GF.

Cell Cycle. 2004 Apr;3(4):469-71. Epub 2004 Apr 1.

PMID:
14752276
34.

Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage.

Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, Hershko A, Pagano M, Draetta GF.

Nature. 2003 Nov 6;426(6962):87-91.

PMID:
14603323
35.

Regulating mammalian checkpoints through Cdc25 inactivation.

Donzelli M, Draetta GF.

EMBO Rep. 2003 Jul;4(7):671-7. Review.

36.

Modulation of p120E4F transcriptional activity by the Gam1 adenoviral early protein.

Colombo R, Draetta GF, Chiocca S.

Oncogene. 2003 May 1;22(17):2541-7.

PMID:
12730668
37.

The adenovirus protein Gam1 interferes with sumoylation of histone deacetylase 1.

Colombo R, Boggio R, Seiser C, Draetta GF, Chiocca S.

EMBO Rep. 2002 Nov;3(11):1062-8. Epub 2002 Oct 22.

38.

Dual mode of degradation of Cdc25 A phosphatase.

Donzelli M, Squatrito M, Ganoth D, Hershko A, Pagano M, Draetta GF.

EMBO J. 2002 Sep 16;21(18):4875-84.

39.

Histone deacetylase 1 inactivation by an adenovirus early gene product.

Chiocca S, Kurtev V, Colombo R, Boggio R, Sciurpi MT, Brosch G, Seiser C, Draetta GF, Cotten M.

Curr Biol. 2002 Apr 2;12(7):594-8.

40.

p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis.

Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, Meloche S.

EMBO J. 2001 Dec 3;20(23):6672-82.

41.

Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis.

Molinari M, Mercurio C, Dominguez J, Goubin F, Draetta GF.

EMBO Rep. 2000 Jul;1(1):71-9.

42.

Proteasome-dependent degradation of p27/kip1 in gliomas.

Piva R, Cancelli I, Cavalla P, Bortolotto S, Dominguez J, Draetta GF, Schiffer D.

J Neuropathol Exp Neurol. 1999 Jul;58(7):691-6.

PMID:
10411338
43.

Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation.

Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M.

Genes Dev. 1999 May 1;13(9):1181-9.

44.

UBPY: a growth-regulated human ubiquitin isopeptidase.

Naviglio S, Mattecucci C, Matoskova B, Nagase T, Nomura N, Di Fiore PP, Draetta GF.

EMBO J. 1998 Jun 15;17(12):3241-50.

46.

Interaction between Cdc37 and Cdk4 in human cells.

Lamphere L, Fiore F, Xu X, Brizuela L, Keezer S, Sardet C, Draetta GF, Gyuris J.

Oncogene. 1997 Apr 24;14(16):1999-2004.

47.

Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M.

Nat Med. 1997 Feb;3(2):231-4.

PMID:
9018245
48.
49.

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M.

Science. 1995 Aug 4;269(5224):682-5.

PMID:
7624798
50.

Mammalian G1 cyclins.

Draetta GF.

Curr Opin Cell Biol. 1994 Dec;6(6):842-6. Review.

PMID:
7880531

Supplemental Content

Loading ...
Support Center